WO2022131282A1 - Savon, désinfectant, stérilisateur et détergent contenant des algues et un extrait d'algues - Google Patents

Savon, désinfectant, stérilisateur et détergent contenant des algues et un extrait d'algues Download PDF

Info

Publication number
WO2022131282A1
WO2022131282A1 PCT/JP2021/046202 JP2021046202W WO2022131282A1 WO 2022131282 A1 WO2022131282 A1 WO 2022131282A1 JP 2021046202 W JP2021046202 W JP 2021046202W WO 2022131282 A1 WO2022131282 A1 WO 2022131282A1
Authority
WO
WIPO (PCT)
Prior art keywords
test
virus
disinfectant
seaweed
seconds
Prior art date
Application number
PCT/JP2021/046202
Other languages
English (en)
Japanese (ja)
Inventor
正一 中村
Original Assignee
正一 中村
日本エー・シー・ピー株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 正一 中村, 日本エー・シー・ピー株式会社 filed Critical 正一 中村
Publication of WO2022131282A1 publication Critical patent/WO2022131282A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N47/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid
    • A01N47/40—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid the carbon atom having a double or triple bond to nitrogen, e.g. cyanates, cyanamides
    • A01N47/42—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid the carbon atom having a double or triple bond to nitrogen, e.g. cyanates, cyanamides containing —N=CX2 groups, e.g. isothiourea
    • A01N47/44—Guanidine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N59/00—Biocides, pest repellants or attractants, or plant growth regulators containing elements or inorganic compounds
    • A01N59/12—Iodine, e.g. iodophors; Compounds thereof
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N65/00—Biocides, pest repellants or attractants, or plant growth regulators containing material from algae, lichens, bryophyta, multi-cellular fungi or plants, or extracts thereof
    • A01N65/03—Algae
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01P—BIOCIDAL, PEST REPELLANT, PEST ATTRACTANT OR PLANT GROWTH REGULATORY ACTIVITY OF CHEMICAL COMPOUNDS OR PREPARATIONS
    • A01P1/00—Disinfectants; Antimicrobial compounds or mixtures thereof
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01P—BIOCIDAL, PEST REPELLANT, PEST ATTRACTANT OR PLANT GROWTH REGULATORY ACTIVITY OF CHEMICAL COMPOUNDS OR PREPARATIONS
    • A01P3/00—Fungicides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
    • A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
    • A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
    • A23G3/42—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds characterised by the carbohydrates used, e.g. polysaccharides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
    • A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
    • A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
    • A23G3/48—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing plants or parts thereof, e.g. fruits, seeds, extracts
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G4/00—Chewing gum
    • A23G4/06—Chewing gum characterised by the composition containing organic or inorganic compounds
    • A23G4/10—Chewing gum characterised by the composition containing organic or inorganic compounds characterised by the carbohydrates used, e.g. polysaccharides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/734—Alginic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10—Carbonates; Bicarbonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/18—Iodine; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/02—Algae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/02—Algae
    • A61K36/03—Phaeophycota or phaeophyta (brown algae), e.g. Fucus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9706—Algae
    • A61K8/9711—Phaeophycota or Phaeophyta [brown algae], e.g. Fucus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9706—Algae
    • A61K8/9722—Chlorophycota or Chlorophyta [green algae], e.g. Chlorella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • A61Q11/02—Preparations for deodorising, bleaching or disinfecting dentures
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/10—Washing or bathing preparations
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/02—Inorganic compounds ; Elemental compounds
    • C11D3/04—Water-soluble compounds
    • C11D3/10—Carbonates ; Bicarbonates
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/16—Organic compounds
    • C11D3/20—Organic compounds containing oxygen
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/16—Organic compounds
    • C11D3/26—Organic compounds containing nitrogen
    • C11D3/33—Amino carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/16—Organic compounds
    • C11D3/38—Products with no well-defined composition, e.g. natural products
    • C11D3/382—Vegetable products, e.g. soya meal, wood flour, sawdust
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/06—Inactivation or attenuation by chemical treatment
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present invention contains natural materials and their extracted components, which have been ingested by humans for many years and whose safety has been confirmed, as the main components of their medicinal properties, inactivates viruses, and disinfects fungi such as Escherichia coli and yellow staphylococcus.
  • For sanitary agents such as cleaning agents.
  • the present invention relates to the above-mentioned soaps, disinfectants, bactericides and detergents, and the present invention relates to a vaccine for inactivating a specific virus or a drug for preventing or curing a specific disease. do not have.
  • the human mouth is the digestive system that first takes food into the body when ingesting food and drink, and is therefore the first place to be eroded by foreign substances such as fungi, bacteria, and viruses from the outside world.
  • the respiratory organs including the nostrils are also the places where foreign substances such as fungi, bacteria, and viruses are first easily eroded from the outside world.
  • the nasal passages and throat are the respiratory organs that first take in air (oxygen) from breathing into the body (lungs) and are formed integrally with the oral cavity, and the nasal cavity and throat are the airways (trachea) and lungs (lungs). It is connected to the respiratory organs of. Therefore, like the oral cavity, it is the first place to be easily eroded by foreign substances such as fungi and viruses from the outside world.
  • the nutrients and water taken into the body in this way are oxidized in various parts of the body by combining with oxygen taken in from the throat organs (nose, mouth, throat) and the respiratory organs connected to them (airway and lungs).
  • the active energy of the living body is generated, and human body tissues such as meat and bone are formed.
  • Humans are infected with respiratory diseases such as pneumonia and bronchitis because the mucous membrane of the throat such as the nose, throat or trachea contains the causative virus or bacteria.
  • the salivary glands include a large number of salivary glands such as the submandibular gland, the parotid gland, and the sublingual gland, and secrete saliva as an aid to digestion.
  • respiratory and digestive disorders caused by viruses and bacteria may rarely pass through mucous membranes such as the skin or eyes, but most of them are with the throat (mouth, throat and trachea) for breathing. , It results from entering the body via the oral cavity (lips, mouth, teeth, tongue, esophagus) that takes in food and drink.
  • virus and bacterial infections spread from infected people to things and from things to people, rather than directly from person to person.
  • influenza virus new coronavirus, etc. attached to the touch panel of smartphones and buttons of remote controllers of various electric products continue to be activated on the touch panel for about 10 days to 2 weeks. It has been announced by a research institution. Furthermore, it has been reported that viruses and fungi attached to food packages placed on the shelves of retail stores and straps of trains and the like are not killed for at least one week.
  • the mucous membrane in the oral cavity is a part of the mucous membrane of the digestive organs and is also an auxiliary institution for taste. Since the mucous membrane easily absorbs chemical substances with a smaller molecular weight than the outer skin, it can be said that it also plays a role as an absorptive organ because food tends to stay in the oral cavity.
  • the mouth is an entrance to the digestive system and an oxygen intake, and is one of the extremely important holes opened on the surface of the body.
  • muscles for taking in (swallowing) food are developed.
  • an organ for taking in food and cutting it is attached to the surrounding area. Their shape also varies greatly depending on the type of food taken in.
  • a person coughs, sneezes, or blows his nose when he / she tries to expel foreign substances such as dust taken into the nasal cavity or trachea to the outside of the body, or when he / she feels inflammation in the nasal cavity or bronchus. Sneeze.
  • people often touch their fingers with their mouths and noses on a daily basis. This spreads the infection from dye to thing and from thing to person.
  • oral cavity in the present application
  • oral cavity are the digestive organs that first take food into the body when ingesting food and drink and drinking water.
  • Periodontal disease which is one of the oral diseases, is said to affect about 80% of adults in Japan at present.
  • Periodontal disease often means this periodontal disease, and the periodontal tissues (ginger, cementum, periodontal ligament, alveolar bone) that support the teeth are inflamed by various bacteria and vary. It is a disease that causes symptoms. When inflammation occurs only in the gingiva due to multiple causative bacteria that cause periodontal disease, it is called periodontitis, and when inflammation spreads to the periodontal ligament and alveolar bone, which is the periodontal tissue, it is called periodontal disease. ..
  • Glycoprotein which is one of the saliva components in the oral cavity, forms a highly sticky film called plaque on the surface of the tooth.
  • Pg Porphyromonas gingivalis
  • Streptococcus mutans which is one of the worm teeth bacteria, has been found to be infected orally, but periodontal disease bacteria such as Porphyromonas gingivalis (Pg bacterium), which is a periodontal disease bacterium, are found to be infected.
  • Pg bacterium Porphyromonas gingivalis
  • the source of infection is not always clear, including oral infections, contact infections with fingers, food infections through the digestive organs, and droplet infections through the oral cavity, nasal cavity, and respiratory organs including the throat and airways. The possibility of airborne infection has also been pointed out.
  • viruses that cannot self-proliferate do not directly infect human cells, but rather bacteria that are orders of magnitude larger ( ⁇ m level) than viruses. It has also been pointed out that the virus may be transmitted to the human body via the bacteria after the virus is infected and boarded and the virus gene is increased in the host bacterium.
  • saliva is recognized to have antiviral and bactericidal effects
  • the amount of saliva produced per day decreases with age. It is easy to get infected with the fungus, and if it gets infected, it is easy to get serious.
  • the virus adheres to an article or the surface of the human body in a cold environment (low temperature and low humidity), it survives for a relatively long time without dying, especially for lowering the temperature of the respiratory organs including the human throat. Due to the dryness of the fibers on the inner wall of the upper respiratory tract and the decrease in the activity of the fibers (upper respiratory tract barrier function), infection is transmitted from person to person through items that humans touch on a daily basis, rather than in a warm environment. spread.
  • Tamiflu as a therapeutic agent for influenza
  • Remdecibel gene: Bekulley
  • favipiravir gene: Avigan
  • these therapeutic agents have a risk of causing side effects on pregnant women and idiosyncratic drugs, and considering the risk of the emergence of resistant viruses, first of all, they should not be infected and should not infect others. It is important to avoid contact between people as much as possible, and to disinfect and clean the articles that people come into contact with.
  • the new coronavirus at present, for example, the number of people infected with the coronavirus and the number of deaths of Japanese (including people in East Asia such as China, South Korea, and Taiwan) are in other developed countries in terms of population ratio. It is also a fact that it is low compared to the Western countries.
  • disinfectants and disinfectants according to the present invention for example, detergents for tableware including cutting boards and detergents for fruits and vegetables often have a small amount of unrinsed residue entering the digestive organs such as the esophagus. be.
  • soaps for hand washing and disinfectants used for disinfecting fingers and the like Therefore, it is desirable that these disinfectants and disinfectants have been confirmed to be safe even if they are ingested by the human body.
  • the inventor of the present application is a natural material that people in East Asia, including Japanese, usually eat a lot on a daily basis, and Western countries do not usually eat. Focusing on this, we conducted tests to confirm the antiviral effect, virus inactivating effect, and bactericidal effect of Escherichia coli and Staphylococcus aureus, which are such natural and natural materials that prevent human virus infection. ..
  • the virus inactivating effect of such a natural material is confirmed, from a group consisting of proteoglycan, mucopolysaccharide (for example, glycosaminoglycan, etc.), and a sugar chain-peptide isolate of proteoglycan. At least one selected has a virus inactivating effect, and further, a proteoglycan-containing extract obtained from Amefurashi and Namako, particularly from Namako, and a sugar chain-peptide isolate of proteoglycan in the extract. , Documents showing that it has a high virus inactivating effect are disclosed (see Patent Document 1).
  • the present invention contains natural materials and their extracted components, which have been ingested by humans for many years and whose safety has been confirmed, as the main components of their medicinal properties, inactivates viruses, and disinfects fungi such as Escherichia coli and yellow staphylococcus.
  • Disinfectants used to disinfect soaps that have a physiological effect to sterilize or disinfect, disinfectants used to disinfect fingers, etc., disinfectants for cleaning and disinfecting items such as furniture, floors, handles of trains and buses, etc. It provides a disinfectant, as well as a cleaning agent for cleaning tableware, cutting boards, foods containing vegetables and fruits, and the like.
  • respiratory diseases and digestive diseases caused by viruses and bacteria are often transmitted from an object to a person through an article touched by an infected person, and in many cases, a person's throat (mouth, throat and trachea) or eating and drinking. It enters the body via the oral cavity (lips, mouth, teeth, tongue, esophagus) that takes things in.
  • the hygiene-related agent according to the present invention is excellent as a soap, a disinfectant, a bactericidal agent, and a cleaning agent for cleaning tableware and food. In addition, even a small amount of this should not cause any problems even if it touches sensitive mucous membranes such as the throat, nostrils, and oral cavity of the human body.
  • the applicant of the present application submits a natural / natural material, seaweed, according to the present invention, prior to carrying out various detailed and long-term effect confirmation tests described in detail in the specification of the present application. And / or the extract thereof does not cause any discomfort even if it touches the sensitive throat, nostrils, oral cavity, bronchi, etc. of the human body even in a small amount, and the hygiene-related agent according to the present invention is virus-free.
  • the applicant of the present application crushed the seaweed and / or an extract thereof according to the present invention into a size of approximately 5 ⁇ m extremely finely, and powder of this ultrafine size was subjected to physiological saline (a physiological saline solution (). It was confirmed that if it is dissolved in cold water and boiling water and taken or ingested, it can be ingested or taken without any discomfort as a hygiene-related agent such as a detergent or a disinfectant. Therefore, in the 1st to 10th effect confirmation tests described later, the seaweed and / or its extract according to the invention is pulverized to a size of approximately 5 ⁇ m extremely finely, and this ultrafine size powder is physiologically used. It was dissolved in saline solution (cold water and boiling water).
  • the physiological saline solution is an aqueous solution of sodium chloride (NaCl) prepared to have almost the same osmotic pressure as human body fluid.
  • NaCl sodium chloride
  • a saline solution containing 0.9 w / v% of sodium chloride is defined as "physiological saline solution”.
  • the inventor and applicant of the present application focus on a plurality of natural foods that many Western countries have few opportunities to eat from among the foods and foods that Japanese people eat on a daily basis.
  • the inactivation of various viruses played by the various selected foodstuffs and the bactericidal and cleaning effects on various bacteria were actually confirmed by several tests over a long period of time. be.
  • seaweeds such as kelp, wakame seaweed, and sea lettuce or extracts of such seaweeds have a remarkable virus-reducing effect and a virus-inactivating effect, and a remarkable cleaning effect that kills bacteria such as Escherichia coli and yellow staphylococcus.
  • Test effects such as bactericidal or sterilizing action, disinfecting action, etc. were confirmed.
  • the present invention contains seaweeds such as kelp, wakame, and blue-green algae and / or extracts thereof as the main components of the medicinal effect, and has an inactivating effect on viruses and a bactericidal effect on bacteria including Escherichia coli and Staphylococcus aureus. , Soaps, disinfectants, disinfectant disinfectants or cleaning agents.
  • the soaps are hand-washing or bathroom soaps including solid soap, liquid soap, and shampoo
  • the disinfectant is a liquid or spray-like disinfectant used for disinfecting fingers and the like.
  • Disinfectant / disinfectant is a disinfectant / disinfectant for disinfecting / disinfecting furniture, floors, handles of trains and buses, and cleaning agents are tableware, cutting boards, foods containing vegetables and fruits, etc. Means a cleaning agent for cleaning.
  • these sanitary agents include soaps, disinfectants, disinfectants and additives to be added to detergents.
  • the present invention contains seaweeds such as kelp, wakame, and blue-green algae and / or extracts thereof, and ethyl alcohol, and has an inactivating action against viruses and a bactericidal action against bacteria including Escherichia coli and Staphylococcus aureus. It provides a soap, a disinfectant, a disinfectant disinfectant, or a cleaning agent.
  • ethyl alcohol is known to exert a bactericidal action by itself, but in the present invention, seaweeds such as kelp, wakame seaweed, and sea lettuce and / or an extract thereof are used together with a medicinal action. This made it possible to increase the cleaning action, sterilizing or sterilizing action, and disinfecting action. In addition, by greatly reducing the amount of ethyl alcohol used, the irritation of alcohol is weakened, and children and babies can use it for a long period of time with peace of mind.
  • the present invention contains seaweeds such as kelp, wakame, and blue-green algae and / or extracts thereof, ethyl alcohol, and surfactants, and contains Escherichia coli and Staphylococcus aureus with an inactivating action against viruses. It provides a soap, a disinfectant, a disinfectant disinfectant or a cleaning agent having a bactericidal action against bacteria.
  • the surfactant is a general term for substances having a hydrophilic group that is easily compatible with water and a lipophilic group that is easily compatible with oil in its molecule, and is the main component of detergents such as soap. Since the free energy of the interface becomes high and destabilizes in the vicinity of this interface, the interface tries to reduce the surface surface as much as possible, and a substance having an amphipathic chemical structure having a hydrophilic group and an oil-based group in one molecule is the interface. By lining up on top, it has the property of alleviating this unstable state. Surfactants are used in large quantities for detergent applications and also occupy an important position as emulsifiers and moisturizers for foods and cosmetics.
  • seaweeds such as kelp, wakame seaweed, and sea lettuce and / or their extracts are synergistic with the above-mentioned action and effect of the hydrophilic group of the surfactant and the parent oil group, thereby inactivating the illus and Escherichia coli. And the bactericidal action against bacteria including Staphylococcus aureus can be enhanced extremely effectively.
  • the virus contains SARS-CoV-2 and influenza virus.
  • the seaweed extract is one or more of fucoidan, laminarin, arginine, potassium alginate, mannuronic acid, gluronic acid, or iodine, which are viscous polysaccharides later revealed in the results of several experiments. It is a combination of.
  • Fucoidan, laminarin, arginine, sodium alginate, mannuronic acid and gluronic acid are stored polysaccharides contained in seaweeds and mushrooms and are easily extracted with water, and most of them are viscous components for a long time. It is known to have antitumor activity, antithrombotic activity, and antihypertensive activity. It was confirmed by this test that these extracts also have a virus inactivating effect and a bactericidal effect in addition to these conventionally known effects.
  • Citric acid and baking soda have been confirmed to have cleaning and bactericidal effects by themselves and others.
  • aminolevulinic acid and / and L-glutamic acid are added to the hygiene-related agent according to the present invention.
  • aminolevulinic acid is a starting material of the porphyrin synthesis pathway and is a substance used in plastids of prokaryotes and eukaryotes.
  • a virus caused by 5-aminolevulinic acid (5-ALA) has been introduced.
  • the virus infection suppressing effect was confirmed.
  • a more remarkable virus infection suppressing effect was confirmed by the combined use with seaweed and its extract.
  • the hygiene-related agent according to the present invention has an enhanced cleaning action and bactericidal action.
  • polyphenols are components of bitterness and pigments present in most plants, and generally, like vitamin C and vitamin E, have a strong antioxidant effect and are harmless to harmful substances such as active oxygen. It is known to be useful for the prevention of lifestyle-related diseases such as the action of changing vitamins and arteriosclerosis. In the present invention, a remarkable virus infection suppressing effect was confirmed by the combined use with seaweed and its extract.
  • red wine contains polyphenols and alcohol and the secretion of saliva is promoted by a slight acidity, it is understood that it is one of the best foods and drinks for inactivating the virus.
  • ⁇ -carotene may be added to the hygiene-related agent according to the present invention.
  • ⁇ -carotene has an antioxidant effect and an immunostimulatory effect. It was confirmed that alcohol for drinking was used in combination with seaweed and its extract as a hygiene-related agent according to the present invention to suppress virus infection.
  • the hygiene-related agents according to the present invention are all natural or naturally derived foodstuffs, their constituent elements and safe materials for additives, and SARS-CoV-2 is subjected to a strict confirmation test described later.
  • SARS-CoV-2 is subjected to a strict confirmation test described later.
  • the inactivating action against various viruses including Escherichia coli and the bactericidal action against bacteria including Escherichia coli and Staphylococcus aureus were confirmed.
  • the seaweed extract is produced by dissolving dried seaweed powder in a saline solution or a physiological saline solution, and is used by contacting or staying in contact with the human body for at least 30 seconds.
  • the salt weight ratio in the saline solution or physiological saline solution is 0.9 to 3.4%.
  • the present invention does not cause side effects like a vaccine, and it does not have an infection-preventing effect against only a specific virus like a vaccine, but by taking or ingesting it on a daily basis without difficulty.
  • Vaccines, disinfectants, and bactericidal agents that make it difficult to be infected with various viruses including SARS-CoV-2 or do not worsen the symptoms even if infected, and also have a sterilizing or bactericidal effect on Escherichia coli and yellow staphylococcus. And cleaning agents can be provided.
  • PED virus which is a coronavirus similar to the form of SARS-CoV-2.
  • seaweed kelp constituting the soaps, disinfectants, disinfectants and cleaning agents according to the present invention about each of the main constituents of seaweeds such as alginic acid, fucoidan and iodine, and further, alginic acid + fucoidan.
  • the test result (2) of the effect on the new coronavirus "SARS-CoV-2" with respect to the mixed component of + iodine is shown.
  • the test result (3) of the effect on PED virus which added alcohol to the sanitary agent such as soaps, disinfectants, bactericides, detergents of this invention is shown.
  • the test result (4) of the effect against a virus is shown.
  • the test result (5) of the bactericidal effect on Escherichia coli by the sanitary agent of this invention is shown.
  • the test result (5) of the bactericidal effect against Staphylococcus aureus by the sanitary agent of the present invention is shown.
  • PED virus for each of the elements or additives constituting the sanitary agent of the present invention L-glutamic acid, ⁇ -carotene ( ⁇ -carotene), aosa, red wine (containing 14% alcohol and polyphenols), laminarin and fucoidan.
  • the test result (6) of the effect on the above is shown.
  • the test result (7) of the action effect with the hygiene agent of this invention against influenza virus is shown.
  • the test result (8) of the effect on the new coronavirus SARS-CoV-2 by the sanitary agents such as soaps, disinfectants, bactericides and cleaning agents according to the present invention is shown.
  • Porfilmo that causes periodontal disease due to soap, disinfectant, bactericidal agent, seaweed kelp powder constituting the cleaning agent, fucoidan powder, Tamaro tea leaf powder, which are the main components thereof, and a mixture thereof.
  • the test result (9) of the effect on the eggplant-zingivalis bacterium is shown.
  • Periodontal disease is caused by soap, disinfectant, bactericidal agent, seaweed kelp powder constituting the cleaning agent, fucoidan powder, which is the main component thereof, Tamaro tea leaf powder (Tamaro powder), and a mixture thereof.
  • the test result (10) of the effect on the Porphyllmonas gingivalis bacterium to be caused is shown.
  • the antiviral agent or virus inactivating agent contained in sanitary agents such as soaps, disinfectants, bactericides and cleaning agents and foodstuffs according to the present invention is kelp or seaweed and seaweed extract belonging to brown algae. Derived from the product extracted from.
  • Kelp belongs to seaweed, and seaweed is a general term for algae that grow in the sea. Unlike seagrass, algae do not bloom and grow offspring by spores. Most seaweeds are edible.
  • Seaweed is classified into blue algae, diatoms, green algae, brown algae, red algae, etc. according to color, and kelp belongs to brown algae.
  • the difference in the color of kelp depends on the water depth of the place where seaweed grows, that is, the amount of sunlight that reaches, and the shallow water is green, the deep place is brown, and the place where the light is most difficult to reach is red.
  • Many of the brown algae to which kelp belongs include wakame seaweed, hijiki seaweed, mozuku seaweed, and mekabu.
  • Green laver belongs to green algae, and gliopeltis and amanori belong to red algae.
  • kelp which is a cold current brown algae, is distributed in the Pacific coast north of Miyagi prefecture and the sea throughout Hokkaido, and Hokkaido is the main production area. Most of the domestic production of kelp is taken from Hokkaido.
  • Kelp contains arginine, alginic acid, and fucoidan, a unique viscous polysaccharide that exists only in seaweeds.
  • arginine is known to have an effect of lowering blood pressure
  • fucoidan is known to have an effect of preventing thrombosis and cancer.
  • Fucoidan is a type of sulfated polysaccharide. It is a dietary fiber that is abundant in the mucilage of brown algae such as kelp, wakame seaweed (including mekabu, which is a part of it), and mozuku. Similar substances have also been found in animals such as sea cucumbers having an antiviral activity described in Patent Document 1 described above.
  • Alginic acid, alginic acid, and fucoidan contained in kelp are compounds in which tens to hundreds of thousands of L-fucose (polysaccharides) are linked by A1-2 and A1-4 bonds. The average molecular weight is about 200,000. Fucoidan is classified into U-fucoidan containing glucuronic acid, F-fucoidan consisting only of sulfated fucose, and G-fucoidan containing galactose.
  • L-fucose has a sulfate group bonded to fucose.
  • This L-fucose is abundantly contained in brown algae (Mozuku, Mekabu, Kombu, Akamoku, Sargassum fulvelus such as Sargassum thunbergii, etc.) and is often expressed as a sticky component of seaweed.
  • arginine is an acidic polysaccharide composed of two types of uronic acid called mannuronic acid (M) and gluronic acid (G). Since arginine greatly changes in hardness and elasticity depending on the ratio of (M) and (G) bound, it can be used as a material for pudding, jelly, ice cream, jam, etc., for emulsification purposes such as yogurt, cheese, etc. It is used for various purposes such as artificial ice cream, and in kelp, it is combined with calcium and magnesium and exists in a jelly state.
  • M mannuronic acid
  • G gluronic acid
  • arginine is known to have the following physiological actions (1) to (3).
  • (1) Action to lower blood pressure Excessive intake of salt upsets the balance between sodium and potassium ions in the blood and causes blood vessels to constrict, resulting in an increase in blood pressure.
  • potassium alginate which is bound to potassium among arginine
  • arginine separates potassium by gastric acid. After that, it moves to the intestine and binds to the sodium ions contained in the food taken with it and carries it out of the body.
  • potassium separated from arginine becomes potassium ions and is absorbed from the intestine, and has the function of expelling sodium in the blood.
  • arginine has a dual function of lowering blood pressure.
  • (2) Action to activate the action of digestive enzymes When sodium alginate is ingested with food, it promotes digestion by enhancing the actions of amylase and protease in the intestine, which are digestive enzymes.
  • (3) Action to remove harmful substances Accumulation of harmful substances and pollutants in the body causes various abnormalities and diseases.
  • arginine was given to an experimental animal contaminated with radioactive strontium, it has been reported that it has a function of excreting the radioactive element from the body.
  • kelp is rich in dietary fiber, and the main components of the dietary fiber are arginine and fucoidan, which have a different chemical structure from the dietary fiber contained in vegetables and grains.
  • the slime component of kelp contains these two polysaccharides.
  • amino acids forming umami and mannitol having a sweet taste are present as components other than dietary fiber.
  • minerals such as magnesium and calcium, and iodine are also contained as nutritional components, making it an excellent food that meets the purpose of nutritional supplementation.
  • the slip component "fucoidan” contained in the kelp seaweed and the like according to the present invention is said to have a large number of biological activities. For example, anticoagulant action, cell adhesion inhibitory action, anti-inflammatory action, cell protection from viral infection, antitumor action.
  • iodine is a mineral that is essential for the human body and is mainly contained in kelp, etc., and has been used as the main component of mouthwash for a long time to reduce inflammation in the back of the oral cavity and trachea. Has been done.
  • the amount of iodine required for the human body is 0.095 to 0.13 mg per day (kelp: equivalent to 40 to 60 mg), so if you take this on a daily basis, do not exceed this usage limit. It is also necessary to consider.
  • fucoidan a water-soluble dietary fiber contained in kelp, slows the movement of food ingested into the body from the stomach to the small intestine. Fucoidan uses sulfate groups to irritate the gastric mucosa in the stomach where digestion has slowed down.
  • the antiviral agent or the virus inactivating agent containing the product extracted from the kelp or seaweed and the seaweed extract according to the present invention may be a part of the action of such fucoidan.
  • fucoidan and its components contained in kelp may contribute to the enhancement of the defense power of immune cells throughout the body by stimulating the mucosal immune function in the intestine.
  • fucoidan held by M cells existing in the human body When lymphocytes (NK cells, T cells, B cells) attack, NK cells, one of the lymphocytes involved in immunity, are activated, and when the activated lymphocytes get on the blood flow. The secretion of antibodies progresses. As a result, immunity is enhanced.
  • citric acid is an organic compound contained in citrus fruits and the like, and is one of hydroxy acids. Since it has a refreshing acidity, it is often used as a food additive, so there is no problem with its safety.
  • Citric acid is also one of the factors that inhibit glycolytic phosphofructokinase activity and regulate the influx from glycolysis into the citric acid cycle, and is indirectly intramuscular lactic acid in the citric acid cycle. It is said that it also has the effect of reducing fatigue after exercise from the point of decomposing. The reason is that citric acid also forms a chelate complex with calcium, which is one of the fatigue substances, and the binding with calcium is generally predominant in the trade-off with the decrease in acidosis in lactic acid decomposition. It can be effective in reducing fatigue.
  • citric acid promotes saliva secretion when it is eaten.
  • saliva derived from the minor salivary glands saliva derived from the minor salivary glands (palatal gland, tongue gland, cheek gland, lip gland, molar tooth gland, and Ebnel gland) is added to this. At rest, saliva from the submandibular gland is 60-70%. Submandibular gland / sublingual gland The saliva drainage part is the lower part of the tongue (oral floor).
  • saliva secretion is promoted due to its taste-stimulating effect. It has been confirmed that saliva has functions such as digestive action, oral self-cleaning action, oral mucosa protective action, pH regulation, antibacterial action, and antiviral action. In this way, the large amount of saliva excreted by citric acid and the antiviral effect of saliva suppress the prolongation of viral load and infectivity.
  • baking soda is a highly safe food additive that has been conventionally eaten as a baking powder as a weakly alkaline food material for inflating cookies, pancakes, and the like.
  • the baking soda made based on the provisions of the Food Sanitation Law may be used as an antacid for excess gastric acid as a medicine.
  • the gastric fluid contains hydrochloric acid, sodium hydrogen carbonate, which constitutes baking soda, decomposes to generate carbon dioxide bubbles, which stimulate the taste and stomach and promote the secretion of further saliva and gastric fluid. To do.
  • Test material Seaweed and seaweed extract Test material I: Seaweed and seaweed extract were dissolved in physiological saline to prepare a 2% solution.
  • Test material II Seaweed and seaweed extract were dissolved in boiling water (100 ° C) physiological saline to a concentration of 2%, and used after cooling. Here, a sterile phosphate buffer was used as a control material.
  • test microorganism As the test microorganism (virus), a P-5V strain of PED virus (Porcine epidemic diarrhea virus) was used.
  • This PED virus (Porcine epidemic dialrrhea virus) is commonly called a pig infectious disease virus, and the pathogen PED virus belongs to the genus Alphacoronavirus of the coronavirus family and is radial (crown-shaped) on the surface of the envelope. That is, it has a corona-like protruding spike, and its genome is a plus single-stranded RNA. It is the type of coronavirus that most closely resembles the pandemic-infected new coronavirus (COVID-19) in 2020.
  • COVID-19 pandemic-infected new coronavirus
  • the tip of a corona-shaped spike that protrudes radially on the surface of this envelope attaches to the surface of the cell membrane that constitutes the human body, and the virus enters the human body.
  • the virus is infected with the virus.
  • Vero cells were used as cultured cells for PED virus (Porcine epidemic dialrrhea virus). These Vero cells are derived from the kidney epithelial cells of African green monkeys and are a cell line used for cell culture. It is one of the most commonly used cell lines along with Hela Cell.
  • (C) Setting of group As a test group, 0.1 mL of virus solution was added to 1 mL of the above-mentioned test material (2% solution of seaweed and seaweed extract in physiological saline), and the sensitization time was set. , 1 minute after the start of the test.
  • 0.1 mL of virus solution was simply added to 1 mL of phosphate buffer without adding the above-mentioned test materials, and the sensitization time was set to 30 seconds and 1 minute after the start of the test.
  • the sensitization time of the test plot was set to 30 seconds and 60 seconds because it was assumed that the soap, disinfectant, disinfectant, and cleaning agent according to the present invention would come into contact with the skin and mucous membranes of the human body. be.
  • Test method The test method was carried out with reference to "Virus Experiments General Remarks Revised 2nd Edition Maruzen Co., Ltd. Virus Neutralization Test Method".
  • the virus addition concentration was set to 106 TCID 50 / mL or more.
  • the mixture was allowed to stand at room temperature (25 ° C) for a predetermined time.
  • Judgment is made by culturing at 37 ° C in carbon dioxide gas culture (5%) for 5 days, then observing the cultured cells under a microscope, confirming the presence or absence of viral proliferation by CPE (cell degeneration) appearing in the cultured cells, and calculating the concentration. did.
  • FIG. 1 shows the effect of the sanitary agents such as soaps, disinfectants, disinfectants, and cleaning agents according to the present invention on PED virus, which is a coronavirus similar to the form of SARS-CoV-2.
  • Table 1 showing the result (1) is a summary of the test results (1).
  • the vertical axis of FIG. 1 also has the vertical axis of 10 as an exponential notation in the subsequent FIGS. 2 to 7, which means that each time one frame is lowered, it becomes one tenth.
  • the genome of the PED virus (Porcine epidemic dialrrhea virus) is a plus single-stranded RNA, which is the type of coronavirus that most closely resembles the new coronavirus (COVID-19). It was speculated that the inactivating effect on "SARS-CoV-2" was also large.
  • Test material Seaweed and seaweed extract Test material 1: 2% kelp powder particle diameter 5 ⁇ m physiological salt aqueous solution
  • Test material 2 2% kelp powder particle diameter 5 ⁇ m physiological salt aqueous solution (prepared by boiling water dissolution)
  • Test material 3 2% sodium alginate powder physiological salt aqueous solution
  • Test material 4 2% fucoidan powder physiological salt aqueous solution (prepared to dissolve in boiling water)
  • Test material 5 2% iodine powder physiological salt aqueous solution (prepared to dissolve in boiling water)
  • a sterile phosphate buffer solution was used as a control material.
  • SARS-CoV-02 new coronavirus
  • This SARS-CoV-02 is a human-derived isolate, and after isolation and culture using vero cells from saliva, confirmation of amplification of the SARS-CoV-2 gene using real-time PCR (Ministry of Health, Labor and Welfare notification method). It is a virus strain that performed.
  • the cultured cells, vero cells, are cell lines derived from the kidney epithelium of African green monkeys.
  • group (C) As a control group, 0.1 mL of virus solution was added to 1 mL of phosphate buffer, and the sensitization time was set to 30 seconds and 60 seconds after the start of the test.
  • 0.1 mL of virus solution was added to 1 mL of the above test material, and the sensitization time was set to 15 seconds, 30 seconds, and 60 seconds after the start of the test.
  • Test method The test method was carried out with reference to "Virus Experiments General Remarks Revised 2nd Edition Maruzen Co., Ltd. Virus Neutralization Test Method".
  • the cultured cells were inoculated, the maximum concentration indicating the normal state of the cultured cells was confirmed, and the virus concentration used for the test was determined.
  • the cytotoxicity was as shown in the following table, and it was confirmed that the cells grew poorly in the test material 10 times solution at the maximum. Therefore, it was found that in the test, it is necessary to dilute the mixed solution of the test material and the virus solution 10 times or more and then inoculate the cells.
  • the virus addition concentration was 106 TCID 50 / mL or more.
  • the mixture was allowed to stand at room temperature (25 ° C.) for a predetermined time.
  • Judgment was made by culturing at 37 ° C. in carbon dioxide gas culture (5%) for 5 days, then observing the cultured cells under a microscope, confirming the presence or absence of viral proliferation by CPE (cell degeneration) appearing in the cultured cells, and calculating the concentration. ..
  • (F) Results Figure 2 shows the seaweed kelp, which is a sanitary agent such as soaps, disinfectants, disinfectants, and cleaning agents, and the main constituents of seaweeds, alginic acid, fucoidan, and iodine, respectively. Furthermore, the test results of the effect of the mixed component of alginic acid + fucoidan + iodine on the new coronavirus "SARS-CoV-2" are shown. In addition, the details of the test results shown in FIG. 2 are summarized in Tables 2A, 2B and 2C. Note that Table 2C is an easy-to-understand version of Table 2B.
  • Test Group 1 99.7% in 15 seconds and 99.9% in 60 seconds
  • Test Group 2 99.7% in 15 seconds, 99.9% in 60 seconds
  • Test Group 3 15 seconds. 59.3% in 60 seconds, 93.7% in 60 seconds, 97.5% in 15 seconds, 99.7% in 60 seconds, 90.0% in 15 seconds, 99 in 60 seconds in test plot 5.
  • the virus infectivity decreased by 9.0%, 98.4% in 15 seconds, and 99.8% in 60 seconds.
  • the virus infection rate for SARS-CoV-02 described above is generally close to the detection limit, and this test confirmed a surprisingly high virus inactivating effect.
  • seaweed and seaweed extract are 2% solutions, and in the case of kelp powder, the particle size is 5 ⁇ m, so that even if it is applied to the sanitary agent according to the present invention, it can be used without discomfort. It turned out.
  • Test material Seaweed and seaweed extract Test material 1: 2% kelp powder particle diameter 5 ⁇ m physiological salt aqueous solution
  • Test material 2 2% kelp powder particle diameter 5 ⁇ m physiological salt aqueous solution (prepared by boiling water dissolution)
  • Test material 3 1% kelp powder Particle size 5 ⁇ m Physiological salt aqueous solution (prepared to dissolve in boiling water)
  • Test material 4 0.5% kelp powder particle size 5 ⁇ m physiological salt aqueous solution (prepared to dissolve in boiling water)
  • Test material 6 Alcohol content 25 degrees 5% kelp shochu diluted 3 times with purified water (prepared to dissolve in boiling water)
  • a sterile phosphate buffer was used as a control material.
  • test microorganism As the test microorganism (virus), a P-5V strain of PED virus (Porcine epidemic diarrhea virus) was used.
  • the cultured cells are vero cells (cells derived from the kidney epithelium of African green monkeys).
  • test group As the test group, 0.1 mL of virus solution was added to 1 mL of the above-mentioned test material, and the sensitization time was set to 15 seconds, 30 seconds, and 60 seconds after the start of the test.
  • 0.1 mL of virus solution was added to 1 mL of phosphate buffer, and the sensitization time was set to 0 seconds and 60 seconds after the start of the test.
  • Test method The test method was carried out with reference to "Virus Experiments General Remarks Revised 2nd Edition Maruzen Co., Ltd. Virus Neutralization Test Method".
  • the cultured cells were inoculated, the maximum concentration indicating the normal state of the cultured cells was confirmed, and the virus concentration used for the test was determined.
  • the cytotoxicity was as shown in the following table, and it was confirmed that the cells grew poorly in the test material 10 times solution at the maximum. Therefore, it was found that in the test, it is necessary to dilute the mixed solution of the test material and the virus solution 10 times or more and then inoculate the cells.
  • the virus addition concentration was 106 TCID 50 / mL or more.
  • the mixture was allowed to stand at room temperature (25 ° C.) for a predetermined time.
  • Judgment was made by culturing at 37 ° C. in carbon dioxide gas culture (5%) for 5 days, then observing the cultured cells under a microscope, confirming the presence or absence of viral replication by CPE (cell degeneration) appearing in the cultured cells, and calculating the concentration. ..
  • Test Group 1 99.7% in 15 seconds and 99.9% in 60 seconds
  • Test Group 2 99.7% in 15 seconds, 99.9% in 60 seconds
  • Test Group 3 60 seconds. 99.8% in Test Group 4
  • 97.4% in 60 seconds in Test Group 4 93.6% in 60 seconds in Test Group 5, and 97.4% in Test Group 6 60 seconds after the start. rice field.
  • Test material Seaweed and seaweed extract Test material 1: 2% kelp powder physiological salt aqueous solution
  • Test material 2 2% kelp powder physiological salt aqueous solution (prepared by dissolving in boiling water)
  • Test material 3 2% kelp powder aqueous solution
  • Test material 4 2% wakame powder physiological salt aqueous solution
  • Test material 5 2% iodine powder physiological salt aqueous solution
  • Test material 6 2% arginine powder physiological salt aqueous solution
  • Test material 8 2% (iodine + fucoidan + arginine powder)
  • Physiological salt aqueous solution A sterile phosphate buffer was used as a control material.
  • test microorganism As the test microorganism (virus), a P-5V strain of PED virus (Porcine epidemic diarrhea virus) (porcine epidemic diarrhea virus) was used.
  • the cultured cells are vero cells (cells derived from the kidney epithelium of African green monkeys).
  • test group As the test group, 0.1 mL of virus solution was added to 1 mL of the above-mentioned test material, and the sensitization time was set to 15 seconds, 30 seconds, and 60 seconds after the start of the test.
  • 0.1 mL of virus solution was added to 1 mL of phosphate buffer, and the sensitization time was set to 0 seconds, 15 seconds, 30 seconds, and 60 seconds after the start of the test.
  • Test method The test method was carried out with reference to "Virus Experiments General Remarks Revised 2nd Edition Maruzen Co., Ltd. Virus Neutralization Test Method".
  • the cultured cells were inoculated, the maximum concentration indicating the normal state of the cultured cells was confirmed, and the virus concentration used for the test was determined.
  • the cytotoxicity is as shown in the following table. It was confirmed that the cells grew poorly even in the test material 100 times solution at the maximum. Therefore, it was found that in the test, it is necessary to dilute the mixed solution of the test material and the virus solution 100 times or more and then inoculate the cells.
  • the virus addition concentration was 106 TCID 50 / mL or more.
  • the mixture was allowed to stand at room temperature (25 ° C.) for a predetermined time.
  • Judgment was made by culturing at 37 ° C. in carbon dioxide gas culture (5%) for 5 days, then observing the cultured cells under a microscope, confirming the presence or absence of viral replication by CPE (cell degeneration) appearing in the cultured cells, and calculating the concentration. ..
  • test group 1 99.8% in 30 seconds after the start, 99.9% or more in 30 seconds after the start in test group 2, 99.7% in 60 seconds after the start of test in test group 3, and 99.7% in test group 4.
  • 98.4% 60 seconds after the start 98.4% 60 seconds after the start of the test in test group 5, 59.3% 60 seconds after the start in test group 6, 99 60 seconds after the start of the test in test group 7.
  • the virus infectivity decreased by 9.0% and 99.5% in 60 seconds after the start.
  • Test material Seaweed and seaweed extract
  • Test material 1 2% kelp powder physiological salt aqueous solution
  • Test material 2 2% kelp powder physiological salt aqueous solution (prepared by dissolving in boiling water) Sterilized saline was used as a control material.
  • test microorganisms Escherichia coli ATCC117775 and Staphylococcus aureus ATCC6538 were used.
  • the above microorganisms were pre-cultured in nutrient medium and prepared with sterile purified water to a concentration of about 108 CFU / mL, which was used as a test bacterial solution.
  • test group As the test group, 0.1 mL of the test bacterial solution was added to 10 mL of the control material, and the sensitization time was set to 30 seconds and 60 seconds after the start of the test.
  • test bacterial solution 0.1 mL was added to 10 mL of the test material, and the sensitization time was set to 0 seconds, 30 seconds, and 60 seconds after the start of the test.
  • test method was carried out with reference to "JIS Z 2801 (antibacterial processed product-antibacterial test method / bactericidal effect)" and the Phenol coefficient method.
  • Test procedure (E-1) Microbial test method (measurement of bacterial count in test solution) The test solution was appropriately diluted with sterile physiological saline and cultured in nutrient agar medium and each selective medium (Escherichia coli: desoxycholate agar medium and Staphylococcus aureus: egg yolk-added mannit salt medium). The culture was carried out under aerobic conditions at 35 ° C. for 24 to 48 hours, and the populations that grew after the culture were counted to obtain the number of the bacteria.
  • test material The test material and the control material were placed in a sterilized test tube, 0.1 mL of the test bacterial solution was added to 10 mL of the material, and the mixture was well mixed.
  • the number of remaining viable bacteria was measured according to the microbiological test method.
  • test material 1 decreased by 43.7% 60 seconds after contact and the test material 2 decreased by 50.0%.
  • the number of Staphylococcus aureus decreased by 52.1% in the test material 1 60 seconds after contact and by 30.4% in the test material 2.
  • Test material Seaweed, seaweed extract and additives
  • Test material 1 2% L-glutamic acid powder Physiological salt aqueous solution (preparation of boiling aqueous solution)
  • Test material 2 2% ⁇ -carotene powder Physiological salt aqueous solution (prepared to dissolve in boiling water)
  • Test material 3 2% sea lettuce fine particle powder physiological salt aqueous solution (prepared to dissolve in boiling water)
  • Test material 4 Alcohol content 14% red wine liquid
  • Test material 5 1% kelp 5 ⁇ m powder Alcohol content 14% red wine liquid (prepared to dissolve in boiling water)
  • Test material 6 1% Laminarin powder Physiological salt aqueous solution (prepared to dissolve in boiling water)
  • Test material 7 Fucoidan aqueous solution A sterile phosphate buffer solution was used as a control material.
  • test microorganism As the test microorganism (virus), a P-5V strain of PED virus (Porcine epidemic diarrhea virus) (porcine epidemic diarrhea virus) was used.
  • the cultured cells are vero cells (cells derived from the kidney epithelium of African green monkeys).
  • test group As the test group, 0.1 mL of virus solution was added to 1 mL of the above-mentioned test material, and the sensitization time was set to 15 seconds, 30 seconds, and 60 seconds after the start of the test.
  • 0.1 mL of virus solution was added to 1 mL of phosphate buffer, and the sensitization time was set to 0 seconds and 60 seconds after the start of the test.
  • Test method The test method was carried out with reference to "Virus Experiments General Remarks Revised 2nd Edition Maruzen Co., Ltd. Virus Neutralization Test Method".
  • the cultured cells were inoculated, the maximum concentration indicating the normal state of the cultured cells was confirmed, and the virus concentration used for the test was determined.
  • the cytotoxicity was as shown in Table 6A, and it was confirmed that the cells grew poorly in the test material 10 times solution at the maximum. Therefore, it was found that in the test, it is necessary to dilute the mixed solution of the test material and the virus solution 10 times or more and then inoculate the cells.
  • the virus addition concentration was 106 TCID 50 / mL or more.
  • Judgment was made by culturing at 37 ° C. in carbon dioxide gas culture (5%) for 5 days, then observing the cultured cells under a microscope, confirming the presence or absence of viral proliferation by CPE (cell degeneration) appearing in the cultured cells, and calculating the concentration. ..
  • test plot 1 37.5% in 15 seconds and 90.0% in 60 seconds, in test plot 2, 75.3% in 15 seconds, 90.0% in 60 seconds, and in test plot 3, 59 in 15 seconds. .3%, 93.7% in 60 seconds, 37.5% in 15 seconds, 99.7% in 60 seconds, 99.7% in 15 seconds, 99.9% in 60 seconds in test plot 4.
  • Test Group 6 the virus infectivity decreased by 95.9% in 15 seconds and 99.3% in 60 seconds, and in Test Group 7, 98.4% in 15 seconds and 99.8% in 60 seconds.
  • Test material Seaweed and seaweed extract Test material 1: 2% kelp powder particle diameter 5 ⁇ m physiological salt aqueous solution Test material 2: 2% kelp powder particle diameter 5 ⁇ m physiological salt aqueous solution (prepared by boiling water dissolution) A sterile phosphate buffer was used as a control material.
  • test microorganism As the test microorganism (virus), influenza virus (swine influenza virus H1N1 IOWA strain) was used.
  • the cultured cells are MDCK cells (dog kidney-derived cell lines).
  • test group As the test group, 0.1 mL of virus solution was added to 1 mL of the above-mentioned test material, and the sensitization time was set to 15 seconds, 30 seconds, and 60 seconds after the start of the test.
  • 0.1 mL of virus solution was added to 1 mL of phosphate buffer, and the sensitization time was set to 0 seconds and 60 seconds after the start of the test.
  • Test method The test method was carried out with reference to "Virus Experiments General Remarks Revised 2nd Edition Maruzen Co., Ltd. Virus Neutralization Test Method".
  • the cultured cells were inoculated, the maximum concentration indicating the normal state of the cultured cells was confirmed, and the virus concentration used for the test was determined.
  • the virus addition concentration was 106 TCID 50 / mL or more.
  • Judgment was made by culturing at 37 ° C. in carbon dioxide gas culture (5%) for 5 days, collecting the culture supernatant in each well, confirming the presence or absence of virus growth by hemagglutination reaction, and calculating the concentration.
  • Test Group 1 the virus infectivity decreased by 99.3% in 15 seconds and 99.9% in 60 seconds, and in Test Group 2, 99.3% in 15 seconds and 99.9% in 60 seconds.
  • FIG. 8 shows the test result (8) of the effect of the sanitary agent according to the present invention on the new coronavirus SARS-CoV-2.
  • Test material Seaweed and seaweed extract Test material 1: 2% kelp powder particle diameter 5 ⁇ m physiological salt aqueous solution
  • Test material 2 2% kelp powder particle diameter 5 ⁇ m physiological salt aqueous solution
  • Test material 3 2% kelp powder particle diameter 5 ⁇ m physiological salt aqueous solution (preparation of boiling aqueous solution)
  • Test material 4 2% kelp powder particle size 5 ⁇ m physiological salt aqueous solution (preparation of boiling aqueous solution)
  • Test material 6 2% kelp powder particle size 5 ⁇ m physiological salt aqueous solution (preparation of boiling aqueous solution)
  • Test material 7 2% kelp powder Particle size 5 ⁇ m Physiological salt aqueous solution (preparation of boiling aqueous solution)
  • Test material 8 2% laminarin powder physiological sodium chlor
  • test material 1 "test material 2", and “test material 3”-”test material 7" are the same, but this confirms the variation in the effect in the same test state, and this test. I am doing it to know the reliability of the result.
  • SARS-CoV-02 new coronavirus
  • This SARS-CoV-02 is a human-derived isolate, and after isolation and culture using vero cells from saliva, confirmation of amplification of the SARS-CoV-2 gene using real-time PCR (Ministry of Health, Labor and Welfare notification method). It is a virus strain that performed.
  • the cultured cells used here are vero cells (cells derived from kidney epithelium of African green monkeys).
  • group (C) As a control group, 0.1 mL of virus solution was added to 1 mL of phosphate buffer, and the sensitization time was set to 0 seconds and 60 seconds after the start of the test.
  • 0.1 mL of virus solution was added to 1 mL of the above test material, and the sensitization time was set to 15 seconds, 30 seconds, and 60 seconds after the start of the test.
  • Test method The test method was carried out with reference to "Virus Experiments General Remarks Revised 2nd Edition Maruzen Co., Ltd. Virus Neutralization Test Method".
  • the cultured cells were inoculated, the maximum concentration indicating the normal state of the cultured cells was confirmed, and the virus concentration used for the test was determined.
  • the cytotoxicity was as shown in the following table, and it was confirmed that the cells grew poorly in the test material 10 times solution at the maximum. Therefore, it was found that in the test, it is necessary to dilute the mixed solution of the test material and the virus solution 10 times or more and then inoculate the cells.
  • the virus addition concentration was 106 TCID 50 / mL or more.
  • the mixture was allowed to stand at room temperature (25 ° C.) for a predetermined time.
  • Judgment was made by culturing at 37 ° C. in carbon dioxide gas culture (5%) for 5 days, then observing the cultured cells under a microscope, confirming the presence or absence of viral proliferation by CPE (cell degeneration) appearing in the cultured cells, and calculating the concentration. ..
  • Test Group 1 99.3% in 15 seconds and 99.9% in 60 seconds
  • Test Group 2 99.6% in 15 seconds, 99.9% in 60 seconds
  • Test Group 3 15 seconds. 99.7% in 60 seconds, 99.7% in 60 seconds, 99.3% in 15 seconds, 99.9% in 60 seconds, 99.6% in 15 seconds, 99 in 60 seconds in test plot 5.
  • 9.9%, 99.3% in 15 seconds, 99.9% in 60 seconds in test plot 6, 99.6% in 15 seconds, 99.9% in 60 seconds, 15 seconds in test plot 8.
  • the virus infection titer decreased by 0.6%.
  • Table 9 summarizes the virus inactivating effects of each seaweed component.
  • the main components constituting the seaweeds according to the present invention are the new coronavirus "SARS-CoV-2" that causes COVID-21 and its approximation to this "SARS-CoV-2". It was confirmed that it exerts a remarkable inactivating effect (decrease in the number of viruses) against "PED virus” (PEDV). From this, it is expected that the same remarkable inactivating action will be exerted on the mutant of the new coronavirus "SARS-CoV-2".
  • Table 10 is a table summarizing the virus inactivating effect (virus reduction rate) by SARS-CoV-2, PEDV (PED virus), and influenza virus, and 2% kelp powder, physiological saline having a particle size of 5 ⁇ m. The number of tests was increased for physiological saline solution of boiling aqueous solution of 2% kelp powder particle diameter of 5 ⁇ m, which was the same as that of water, and the variation in the inactivation effect was confirmed.
  • the main components constituting the seaweeds according to the present invention are the new coronaviruses "SARS-CoV-2" and "influenza virus” that cause COVID-21.
  • SARS-CoV-2 the new coronaviruses
  • influenza virus a remarkable inactivating effect (a drastic decrease in the number of viruses) against "PED virus” which is similar to "SARS-CoV-2”. From this, it is easy to exert the same remarkable inactivating action against various types of "influenza virus” such as Hong Kong type and Soviet type, and various mutants of "SARS-CoV-2". is expected.
  • Table 11 is a table summarizing the inactivating effect of physiological saline containing 2% powder fine particles of a plurality of types of seaweed (kelp, seaweed, sea lettuce, Ecklonia stolon) against PED virus.
  • Table 12A is a table summarizing the inactivating effect of the seaweed powder according to the present invention on the "PED virus” which is similar to “SARS-CoV-2".
  • the seaweed powder according to the present invention has a remarkable inactivating effect (virus) on the "PED virus” which is similar to "SARS-CoV-2". It was confirmed that the number was drastically reduced).
  • Table 12B shows "SARS-CoV-2" and "SARS-CoV-2", which are similar to the new coronaviruses “SARS-CoV-2” and “SARS-CoV-2”, which cause COVID-21, which are the main components and various additives constituting the seaweeds according to the present invention. It is a table summarizing the inactivating effect on "PED virus”.
  • the main components and various additives constituting the seaweed according to the present invention are the new coronaviruses "SARS-CoV-2" and “SARS-CoV-2” that cause COVID-21. It was confirmed that it had a remarkable inactivating effect (a drastic decrease in the number of viruses) against the similar "PED virus".
  • Table 12C is a table summarizing the inactivating effect of alcohol and liquor containing kelp components on "PED virus” which is similar to the new coronavirus "SARS-CoV-2" which causes COVID-21.
  • Table 12D is a table summarizing the bactericidal effect results of the seaweed powder according to the present invention on Escherichia coli and Staphylococcus aureus.
  • the seaweed powder according to the present invention has a remarkable bactericidal effect against Escherichia coli and Staphylococcus aureus. From this, it can be understood that the seaweed powder according to the present invention has a bactericidal effect against other bacteria that cause food poisoning.
  • Table 13 is similar to the new coronaviruses "SARS-CoV-2" and “SARS-CoV-2” that cause COVID-21, which are the main components and additives constituting the seaweeds according to the present invention. It is a table summarizing the inactivating effect (dramatic decrease in the number of viruses) against "PED virus”.
  • the main components and additives constituting the seaweed according to the present invention are the new coronaviruses "SARS-CoV-2” and “SARS-CoV-2” that cause COVID-21. It was confirmed that it exerts a remarkable inactivating effect (a drastic decrease in the number of viruses) against the "PED virus" which is close to the above.
  • Table 13 shows the "PED virus” which is similar to the new coronaviruses “SARS-CoV-2” and “SARS-CoV-2” that cause COVID-21 in the seaweed powder and its components according to the present invention. It is a table summarizing the inactivating effect on viruses such as “norovirus” and the bactericidal effect on “E. coli” and “yellow staphylococcus”.
  • the seaweed powder and its components according to the present invention are "PED viruses” similar to the new coronaviruses “SARS-CoV-2” and “SARS-CoV-2” that cause COVID-21. It was confirmed that it has a remarkable inactivating effect on viruses such as “Norovirus” and a bactericidal effect on "E. coli” and "Yellow staphylococcus”.
  • FIG. 9 shows the soap, disinfectant, bactericidal agent, and seaweed kelp powder constituting the cleaning agent, fucoidan powder as the main component thereof, Tamaro tea leaf powder (Tamaro powder), and a mixture thereof.
  • the test result (9) of the effect on the porphyllmonas gingivalis bacterium that causes periodontal disease is shown.
  • Test material Seaweed and seaweed extract
  • Test material 1 2% kelp powder Particle size 5 ⁇ m Physiological salt aqueous solution (preparation of boiling aqueous solution)
  • Test material 2 Fucoidan water (prepared to dissolve boiling water)
  • Test material 3 2% fucoidan powder Physiological salt aqueous solution (preparation of boiling aqueous solution)
  • Test material 4 2% gyokuro powder physiological salt aqueous solution (preparation of boiling aqueous solution)
  • Test material 5 2% gyokuro powder + kelp powder particle size 5 ⁇ m physiological salt aqueous solution (preparation of boiling aqueous solution)
  • Test material 6 2% gyokuro powder + 2% fucoidan powder Particle diameter 5 ⁇ m Physiological salt aqueous solution (preparation of boiling aqueous solution)
  • Test microorganism (bacteria) Porphyromonas gingivalis ATCC33277 was used as the donor microorganism (bacteria), and this test microorganism (bacteria) was precultured in a blood medium and concentrated in sterile purified water at a concentration of about 108 cfu / mL. The test bacterial solution was prepared in.
  • group (C) As a control group, 0.1 mL of the test bacterial solution was added to 10 mL of the control material, and the sensitization time was set to 0, 30, and 60 seconds after the start of the test.
  • test group 1-6 0.1 mL of the test bacterial solution was added to 10 mL of the test material, and the sensitization time was set to 30 and 60 seconds after the start of the test.
  • the sensitization time was set to 30 seconds and 60 seconds assuming the time that the dentifrice or the like, which is the oral hygiene product according to the present invention, stays in the oral cavity.
  • test method was carried out with reference to "JIS Z 2801 (antibacterial processed product, antibacterial test method, bactericidal effect)" and the Phenol coefficient method.
  • E Test procedure (E-1) Microbial test method (measurement of bacterial count in test solution) The test solution was appropriately diluted with sterile physiological saline and cultured in blood agar medium. The culture was carried out under anaerobic conditions at 35 ° C. for 10 days, and the populations that grew after the culture were counted to obtain the number of the bacteria. (E-2) Test method The test material and the control material were placed in a sterilized test tube, 0.1 mL of the test bacterial solution was added to 10 mL of the material, and the mixture was thoroughly mixed.
  • Test Results As shown in Table 14, the control group was 1.2 ⁇ 106 CFU / mL, which was almost the same number from the start to the end of the test.
  • test plots 1-6 were as follows 60 seconds after the start of the test.
  • Test group 1 5.3 ⁇ 10 5 CFU / mL (55.8% decrease)
  • Test group 2 6.8 ⁇ 10 5 CFU / mL (43.3% decrease)
  • Test group 3 7.8 ⁇ 10 5 CFU / mL (35.0% decrease)
  • Test group 4 1.0 ⁇ 10 6 CFU / mL (16.6% decrease)
  • Test group 5 8.8 ⁇ 10 5 CFU / mL (26.6% decrease)
  • Test group 6 1.1 ⁇ 10 6 CFU / mL (8.3% decrease) The above values are the average values of the three trials.
  • FIG. 10 shows the soap, disinfectant, bactericidal agent, and seaweed kelp powder constituting the cleaning agent, fucoidan powder as the main component thereof, Tamaro tea leaf powder (Tamaro powder), and a mixture thereof.
  • the test result (10) of the effect on the porphyllmonas gingivalis bacterium that causes periodontal disease is shown.
  • Test material Seaweed, seaweed extract and additives
  • Test material 1 5% kelp powder Particle size 5 ⁇ m
  • Test material 2 0.5% isoprovir methylphenol physiological salt aqueous solution
  • Test material 3 2% iodine powder physiological salt aqueous solution (prepared to dissolve in boiling water)
  • Test material 4 2% iodine powder physiological salt aqueous solution (prepared to dissolve in boiling water)
  • Test material 5 4% fucoidan powder Physiological salt aqueous solution (prepared to dissolve in boiling water)
  • Test material 6 2% laminarin powder physiological salt aqueous solution
  • Test material 7 2% phloroglucinol (polyphenol) powder physiological saline solution (prepared 217488N3 solution for boiling water)
  • Test material 8 2% sodium alginate powder physiological salt aqueous solution (preparation of boiling aqueous solution)
  • Test material 9 2% erythritol powder Physiological salt
  • Test microorganism (bacteria) Porphyromonas gingivalis ATCC33277 was used as the donor microorganism (bacteria), and this test microorganism (bacteria) was precultured in a blood medium and concentrated in sterile purified water at a concentration of about 108 cfu / mL. The test bacterial solution was prepared in.
  • group (C) As a control group, 0.1 mL of the test bacterial solution was added to 10 mL of the control material, and the sensitization time was set to 0, 30, and 60 seconds after the start of the test.
  • test group 1-10 0.1 mL of the test bacterial solution was added to 10 mL of the test material, and the sensitization time was set to 30 and 60 seconds after the start of the test.
  • the sensitization time was set to 30 seconds and 60 seconds because it was assumed that the dentifrice or the like, which is an oral hygiene product according to the present invention, stays in the oral cavity.
  • test method was carried out with reference to "JIS Z 2801 (antibacterial processed product, antibacterial test method, bactericidal effect)" and the Phenol coefficient method.
  • E Test procedure (E-1) Microbial test method (measurement of bacterial count in test solution) The test solution was appropriately diluted with sterile physiological saline and cultured in blood agar medium. The culture was carried out under anaerobic conditions at 35 ° C. for 10 days, and the populations that grew after the culture were counted to obtain the number of the bacteria. (E-2) Test method The test material and the control material were placed in a sterilized test tube, 0.1 mL of the test bacterial solution was added to 10 mL of the material, and the mixture was thoroughly mixed.
  • test Results As shown in Table 16, the control group was 1.2 ⁇ 106 CFU / mL, which was almost the same number from the start to the end of the test.
  • test plots 1-6 were as follows 60 seconds after the start of the test.
  • Test group 1 5.2 ⁇ 10 5 CFU / mL (56.6% decrease)
  • Test group 2 5.2 ⁇ 10 5 CFU / mL (56.6% decrease)
  • Test group 3 1.6 ⁇ 10 5 CFU / mL (86.6% decrease)
  • Test group 4 1.8 ⁇ 10 5 CFU / mL (85.0% decrease)
  • Test group 5 6.2 ⁇ 10 5 CFU / mL (48.3% decrease)
  • Test group 6 2.5 ⁇ 10 5 CFU / mL (79.1% decrease)
  • Test group 7 1.8 ⁇ 10 5 CFU / mL (85.0% decrease)
  • Test group 8 1.1 ⁇ 10 6 CFU / mL (8.3% decrease)
  • Test group 9 1.1 ⁇ 10 6 CFU / mL (8.3% decrease)
  • Test group 10 1.0 ⁇ 10 6 CFU / mL (16.6% decrease) The above values are the average values of the three trials.
  • Table 17 shows. It should be noted that Tables 15A, 15B and 16 are summarized in a table that is easy to understand.
  • the soaps, disinfectants, bactericides and cleaning agents according to the present invention suppress and sterilize the growth of various bacteria present in the oral cavity, airway, and upper gastrointestinal tract, and further, epidemic influenza, parainfluenza, and viruses. It is also effective in inactivating various viruses such as sexual acute bronchitis, pneumonia, measles, and the new coronavirus (SARS-CoV-2) that causes the new coronavirus disease (COVID-19).
  • SARS-CoV-2 new coronavirus
  • COVID-19 new coronavirus
  • the acidity of citric acid promotes saliva secretion when eaten. That is.
  • saliva secretion is promoted due to its taste-stimulating effect.
  • the saliva exerts a digestive action, an oral self-cleaning action, an oral mucosa protective action, a pH regulation, an antibacterial action, and an antiviral action.
  • the seaweed powder constituting the soaps, disinfectants, bactericides and cleaning agents according to the present invention was produced by dissolving in saline or physiological saline (confirmed at a weight ratio of 0.9% in the test). It is desirable that it can be used on a daily basis as a food additive for adding a taste component to foods such as candy and kelp tea and cooked foods because of the use of the product.
  • kelp since kelp usually contains about 5% of fucoidan containing a mucous polysaccharide, influenza-specific secretion of fucoidan (F-type, U-type, G-type) into the trachea of the human body, which has been confirmed conventionally. It is also expected to promote the production of type Ig antibody.
  • the soaps, disinfectants, bactericides and cleaning agents according to the present invention are bacterial infections in which periodontal disease bacteria in periodontal plaque (dental plaque) inflame the hug and destroy surrounding tissues.
  • periodontal disease bacteria in periodontal plaque dental plaque
  • research papers have been published that contribute to diabetes, brain diseases, and heart diseases, and these secondary effects can be expected.
  • the activator does not cause side effects like a vaccine and does not have an infection-preventing action against only a specific virus, but by eating it on a daily basis or ingesting an extract or the like extracted from it. It is expected to inactivate the virus, which has the effect of making it difficult to be infected with various viruses or not aggravating the symptoms even if infected with the virus.
  • the seaweeds and seaweed extracts confirmed to have an inactivating effect on the above-mentioned corona-type virus were produced by dissolving them in saline solution or physiological saline solution (confirmed at a weight ratio of 0.9% in the test). Therefore, it is possible and desirable to use it on a daily basis as a food additive for adding a taste component to foods such as candy and kelp tea and cooked foods.
  • kelp since kelp usually contains about 5% of fucoidan containing a mucous polysaccharide, influenza-specific secretion of fucoidan (F-type, U-type, G-type) into the trachea of the human body, which has been confirmed conventionally. It is also expected to promote the production of type Ig antibody.
  • the sanitary agent according to the present invention is a vaccine that inactivates a specific virus or a specific bacterium. It was possible to provide soaps, disinfectants, disinfectants, and cleaning agents for cleaning dishes and foods that inactivate various viruses and remove various bacteria, instead of disinfecting agents.
  • the hygienic agent according to the present invention is not a specific agent, and even if it is used for a long period of time and a small amount thereof is continuously ingested by the human body, there is no concern that it may cause any health safety. In addition, there is no risk of developing resistant viruses and resistant bacteria.
  • the hygienic agent according to the present invention has an excellent action and effect as a soap, a disinfectant, a bactericidal agent, and a cleaning agent for cleaning tableware and food, and even a small amount thereof has an excellent effect on the throat, nose, and oral cavity of the human body. There is no problem even if you touch sensitive mucous membranes such as.
  • the sensitization time was set to 30 seconds and 60 seconds because the time when these sanitary agents came into contact with the skin and mucous membrane of the human body. As a result, it can be said that it is extremely significant that the remarkable bactericidal effect and virus inactivating effect of various bacteria could be confirmed in such a short time.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Polymers & Plastics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Botany (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Environmental Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pest Control & Pesticides (AREA)
  • Nutrition Science (AREA)
  • Birds (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Agronomy & Crop Science (AREA)
  • Dentistry (AREA)
  • Dermatology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Medical Informatics (AREA)

Abstract

L'invention concerne un savon, un désinfectant, un bactéricide ou un stérilisateur pour le nettoyage et un détergent qui contient un ingrédient naturel et un extrait de celui-ci, dont l'innocuité a été confirmée même de nombreuses années après avoir été mangé, en tant que composant principal pour son effet médicinal, et qui désactive des virus et tue ou stérilise les bactéries. La présente invention concerne un savon, un désinfectant, un bactéricide/stérilisateur ou un détergent qui : contient des algues, telles que le varech, le wakamé, la laitue de mer et/ou des extraits de ceux-ci en tant que composant principal pour leur effet médicinal ; contient des algues, telles que le varech, le wakamé et la laitue de mer et/ou des extraits de ceux-ci, ainsi que de l'alcool éthylique ; et contient en outre des algues, telles que le varech, le wakamé et la laitue de mer et/ou des extraits de ceux-ci, de l'alcool éthylique et un tensioactif ; et a une action de désactivation contre divers virus tels que le virus du SARS-CoV-2, le virus de la grippe et les norovirus, ainsi qu'une action bactéricide contre les bactéries comprenant Escherichia coli et Staphylococcus aureus.
PCT/JP2021/046202 2020-12-15 2021-12-15 Savon, désinfectant, stérilisateur et détergent contenant des algues et un extrait d'algues WO2022131282A1 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP2020-207665 2020-12-15
JP2020207665 2020-12-15
JP2020216563 2020-12-25
JP2020-216563 2020-12-25
JP2021153971 2021-09-22
JP2021-153971 2021-09-22

Publications (1)

Publication Number Publication Date
WO2022131282A1 true WO2022131282A1 (fr) 2022-06-23

Family

ID=82057602

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2021/046202 WO2022131282A1 (fr) 2020-12-15 2021-12-15 Savon, désinfectant, stérilisateur et détergent contenant des algues et un extrait d'algues

Country Status (1)

Country Link
WO (1) WO2022131282A1 (fr)

Citations (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63316733A (ja) * 1987-06-18 1988-12-26 Kureha Chem Ind Co Ltd 抗ウイルス剤
JPH0436228A (ja) * 1990-05-30 1992-02-06 Lion Corp 口腔用組成物
JPH06256792A (ja) * 1993-03-08 1994-09-13 Honsyu Kosan Kk 抗菌性薬用洗浄剤
JPH0948715A (ja) * 1995-08-04 1997-02-18 Lion Corp 口腔用組成物
JPH10273698A (ja) * 1997-03-27 1998-10-13 Taiyo Kagaku Co Ltd 除菌洗浄剤
JP2000044602A (ja) * 1998-07-31 2000-02-15 Takara Shuzo Co Ltd 抗細菌剤
JP2002302454A (ja) * 2001-04-03 2002-10-18 Mitsubishi Heavy Ind Ltd アオサを原料とする抗ウイルス剤
JP2004189648A (ja) * 2002-12-10 2004-07-08 Kumamoto Prefecture 抗ウイルス性物質
JP2005139074A (ja) * 2003-11-04 2005-06-02 Noevir Co Ltd 黄色ブドウ球菌エンテロトキシン産生抑制剤
JP2007217410A (ja) * 2006-01-20 2007-08-30 Tsutomu Yoshida 抗ウイルス組成物、それを含む抗ウィルス剤及び抗ウイルス機能性食品
JP2007230920A (ja) * 2006-03-01 2007-09-13 Toppan Printing Co Ltd 抗菌抗カビ剤
JP2007284361A (ja) * 2006-04-13 2007-11-01 Riken Vitamin Co Ltd ヘリコバクター・ピロリ接着阻害剤
JP2011512319A (ja) * 2007-08-24 2011-04-21 マリノメド バイオテクノロジー ゲゼルシャフト ミット ベシュレンクテル ハフツング 硫酸化多糖を含有する抗ウイルス性組成物
WO2011105431A1 (fr) * 2010-02-24 2011-09-01 森永乳業株式会社 Agent auxiliaire antibactérien comprenant un extrait de konbu au titre de principe actif, composition antibactérienne et aliment ou boisson
JP2011168533A (ja) * 2010-02-18 2011-09-01 Kyosei Seiyaku Kk 抗インフルエンザウイルス剤
JP2013180994A (ja) * 2012-03-02 2013-09-12 Kokando:Kk 単純ヘルペスウイルス２型感染予防剤およびインフルエンザウイルス感染治療剤
JP2017002004A (ja) * 2015-06-15 2017-01-05 理研ビタミン株式会社 バイオフィルム形成抑制剤
JP2018052834A (ja) * 2016-09-27 2018-04-05 林兼産業株式会社 感染性肺炎の予防及び治療用組成物
JP2019189543A (ja) * 2018-04-20 2019-10-31 国立大学法人 熊本大学 抗ヒト免疫不全ウイルス剤組成物

Patent Citations (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63316733A (ja) * 1987-06-18 1988-12-26 Kureha Chem Ind Co Ltd 抗ウイルス剤
JPH0436228A (ja) * 1990-05-30 1992-02-06 Lion Corp 口腔用組成物
JPH06256792A (ja) * 1993-03-08 1994-09-13 Honsyu Kosan Kk 抗菌性薬用洗浄剤
JPH0948715A (ja) * 1995-08-04 1997-02-18 Lion Corp 口腔用組成物
JPH10273698A (ja) * 1997-03-27 1998-10-13 Taiyo Kagaku Co Ltd 除菌洗浄剤
JP2000044602A (ja) * 1998-07-31 2000-02-15 Takara Shuzo Co Ltd 抗細菌剤
JP2002302454A (ja) * 2001-04-03 2002-10-18 Mitsubishi Heavy Ind Ltd アオサを原料とする抗ウイルス剤
JP2004189648A (ja) * 2002-12-10 2004-07-08 Kumamoto Prefecture 抗ウイルス性物質
JP2005139074A (ja) * 2003-11-04 2005-06-02 Noevir Co Ltd 黄色ブドウ球菌エンテロトキシン産生抑制剤
JP2007217410A (ja) * 2006-01-20 2007-08-30 Tsutomu Yoshida 抗ウイルス組成物、それを含む抗ウィルス剤及び抗ウイルス機能性食品
JP2007230920A (ja) * 2006-03-01 2007-09-13 Toppan Printing Co Ltd 抗菌抗カビ剤
JP2007284361A (ja) * 2006-04-13 2007-11-01 Riken Vitamin Co Ltd ヘリコバクター・ピロリ接着阻害剤
JP2011512319A (ja) * 2007-08-24 2011-04-21 マリノメド バイオテクノロジー ゲゼルシャフト ミット ベシュレンクテル ハフツング 硫酸化多糖を含有する抗ウイルス性組成物
JP2011168533A (ja) * 2010-02-18 2011-09-01 Kyosei Seiyaku Kk 抗インフルエンザウイルス剤
WO2011105431A1 (fr) * 2010-02-24 2011-09-01 森永乳業株式会社 Agent auxiliaire antibactérien comprenant un extrait de konbu au titre de principe actif, composition antibactérienne et aliment ou boisson
JP2013180994A (ja) * 2012-03-02 2013-09-12 Kokando:Kk 単純ヘルペスウイルス２型感染予防剤およびインフルエンザウイルス感染治療剤
JP2017002004A (ja) * 2015-06-15 2017-01-05 理研ビタミン株式会社 バイオフィルム形成抑制剤
JP2018052834A (ja) * 2016-09-27 2018-04-05 林兼産業株式会社 感染性肺炎の予防及び治療用組成物
JP2019189543A (ja) * 2018-04-20 2019-10-31 国立大学法人 熊本大学 抗ヒト免疫不全ウイルス剤組成物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KARBASSI ELIKA, ASADINEZHAD AHMAD, LEHOCKÝ MARIAN, HUMPOLÍČEK PETR, VESEL ALENKA, NOVÁK IGOR, SÁHA PETR: "Antibacterial Performance of Alginic Acid Coating on Polyethylene Film", INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, vol. 15, no. 8, pages 14684 - 14696, XP055943069, DOI: 10.3390/ijms150814684 *

Similar Documents

Publication Publication Date Title
US11077052B1 (en) Selected multi-phase treatment for coronavirus respiratory infections
CN104983600B (zh) 溶菌酶口腔护理保健液及其制备方法
AU2018349244B2 (en) N-acetylneuraminic acid compositions and methods of use
JP5673560B2 (ja) 持続性口腔用殺菌消毒液
RU2314119C2 (ru) Нетоксические дизинфектанты слизистых оболочек, содержащие изопропиловый спирт, кунжутное масло, алоэ и лимонное масло
KR101835263B1 (ko) 요로감염증 예방 및 치료를 위한 항균 조성물
CN103908423B (zh) 抗口腔幽门螺杆菌中药牙膏
CN103651599A (zh) 一种公交车专用清洗消毒剂
WO2022131282A1 (fr) Savon, désinfectant, stérilisateur et détergent contenant des algues et un extrait d'algues
WO2022130732A1 (fr) Produit d'hygiène dérivé d'algues marines et d'extrait de celles-ci, pour la cavité buccale, les narines et la gorge
WO2022131283A1 (fr) Aliment et eau potable contenant des algues et leur extrait
WO2014078942A1 (fr) Compositions, utilisations et méthodes de traitement ou de prévention de caries dentaires
US8518435B2 (en) Homeopathic formulation consisting of Bryonia alba and Pulsatilla spp
JP2022094911A (ja) 海藻類及びその抽出物による口腔用、鼻孔用又は咽喉用の衛生用品
CN109077946A (zh) 虾青素的用途
CN107242983A (zh) 一种含艾叶黄酮的漱口水及其制备方法
WO2021186435A1 (fr) Compositions polymères pour administration intranasale
Singh et al. Passion fruit: a fetched passion for dentists
Swathi et al. Oil Pulling and Oral Health: A Review
CN108174922A (zh) 用于制备减缓龋齿和消除口臭的乳制品的基料及其方法
US20180028843A1 (en) Compositions for human dental care
JP2022115106A (ja) 新しい感染症対策として「新型コロナウイルス、ｃｏｖｉｄ－１９を含む多種類の病原体」を殺すか不活性化することによって人体内を副作用無しに消毒する方法、この消毒方法を用いたその新型コロナウイルス感染後の少なくとも初期の治療方法、及び、この消毒方法を用いた感染予防方法
KR20030090121A (ko) 녹차 폴리페놀을 포함하는 항균 조성물 및 그 용도
Kwun et al. Antimicrobial Activities of Propolis against Oral Candidiasis by Candida Albicans-Effect of Microbial Inhibition Using Propolis
US20050202038A1 (en) Composition and method for minimizing residual fecal matter in the perianal area

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21906644

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP